Colibri Seeks Full Federal Circuit Review in Medtronic Patent Case

By Editorial Team

Colibri Heart Valve LLC is urging the full Federal Circuit to reconsider a panel's decision that overturned a $125 million patent infringement judgment against Medtronic's CoreValve unit. Colibri argues that the panel misinterpreted the law, leading to an overly broad application.

The case revolves around a patent dispute involving Medtronic's CoreValve unit and Colibri Heart Valve LLC. The initial judgment favored Colibri with over $125 million in damages, but Medtronic appealed the decision. The panel's ruling overturned the judgment, prompting Colibri to seek a review by the full Federal Circuit.

Colibri's petition for a full Federal Circuit review highlights the company's stance that the panel's interpretation of the law was flawed and resulted in an unjust outcome. The company is seeking to have the decision reconsidered in hopes of reinstating the initial judgment in its favor.

Legal experts anticipate that the full Federal Circuit's review of the case could have significant implications for the broader patent law landscape, particularly in cases involving complex medical technologies like heart valves.

For more information on this developing legal matter, stay tuned for updates as the case progresses through the appellate process.